You just read:

Faster-acting insulin aspart showed a statistically significant reduction in HbA(1c) in type 1 diabetes and a comparable HbA(1c) reduction in type 2 diabetes versus NovoRapid® (insulin aspart)

News provided by

Novo Nordisk Canada Inc.

Jun 13, 2016, 12:40 ET